Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — April 2024

Biotek-snakken — April 2024

Planlagt Fastgjort Låst Flyttet Biotek-snakken
112 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • exitnuE Offline
    exitnuE Offline
    exitnu
    wrote on sidst redigeret af
    #41

    Calliditas Therapeutics: Pareto 16/4-24; Buy - Target SEK 161 / Share price SEK 101.

    1 Reply Last reply
    0
    • exitnuE Offline
      exitnuE Offline
      exitnu
      wrote on sidst redigeret af
      #42

      "Comments
      Calliditas delivered strong Q4 results and with Tarpeyo’s full FDA
      approval granted in December 2023, we have decided to update
      our estimates according to the current trajectory. With the sales
      unleashing full approval(s) and weak competition, ...

      1 Reply Last reply
      0
      • exitnuE Offline
        exitnuE Offline
        exitnu
        wrote on sidst redigeret af
        #43

        ... we remain
        optimistic and expect the first (organically) profitable quarter to be
        Q3 2024 – if the company continues to step up its commercial
        efforts. With the updated forecasts, we have reached a fair value
        of SEK 177 but have decided to maintain our target price of SEK
        161 due to low growth expected for Q1 2024."

        1 Reply Last reply
        0
        • exitnuE Offline
          exitnuE Offline
          exitnu
          wrote on sidst redigeret af
          #44

          "Pareto upprepar köp för Calliditas inför rapporten - fortsatt optimistiska"

          (Finwire)

          1 Reply Last reply
          0
          • F Offline
            F Offline
            Fandel
            wrote on sidst redigeret af
            #45

            Godmorgen...

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #46

              Alvotech And Teva : FDA Approves Selarsdi Injection For Psoriasis And Psoriatic Arthritis https://www.proinvestor.com/investornyt/1145923/alvotech-and-teva-fda-approves-selarsdi-injection-for-psoriasis-and-psoriatic-arthritis

              1 Reply Last reply
              0
              • L Offline
                L Offline
                LP90
                wrote on sidst redigeret af
                #47

                Godmorgen 🙂

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  ProinvestorNEWS
                  wrote on sidst redigeret af
                  #48

                  ULTIMOVACS: Biotekselskapet melder at de vil redusere antall ansatte med 40% slik at de skal ha likviditet til å nå ytterligere to datapunkter - pengene skal etter plan holde til Q4 2025.

                  1 Reply Last reply
                  0
                  • F Offline
                    F Offline
                    Fandel
                    wrote on sidst redigeret af
                    #49

                    Godmorgen...

                    1 Reply Last reply
                    0
                    • L Offline
                      L Offline
                      LP90
                      wrote on sidst redigeret af
                      #50

                      Godmorgen 🙂

                      1 Reply Last reply
                      0
                      • exitnuE Offline
                        exitnuE Offline
                        exitnu
                        wrote on sidst redigeret af
                        #51

                        Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

                        Link Preview Image
                        Calliditas Therapeutics AB

                        Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

                        favicon

                        Calliditas Therapeutics AB (www.calliditas.se)

                        1 Reply Last reply
                        0
                        • F Offline
                          F Offline
                          Fandel
                          wrote on sidst redigeret af
                          #52

                          Godmorgen...

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            LP90
                            wrote on sidst redigeret af
                            #53

                            Godmorgen 🙂

                            1 Reply Last reply
                            0
                            • F Offline
                              F Offline
                              Fandel
                              wrote on sidst redigeret af
                              #54

                              Godmorgen...

                              1 Reply Last reply
                              0
                              • F Offline
                                F Offline
                                Fandel
                                wrote on sidst redigeret af
                                #55

                                Godmorgen...

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #56

                                  BioArctic And Eisai Collaborate On Evaluating BAN2802 For Alzheimer's Disease https://www.proinvestor.com/investornyt/1148131/bioarctic-and-eisai-collaborate-on-evaluating-ban2802-for-alzheimers-disease

                                  1 Reply Last reply
                                  0
                                  • H Offline
                                    H Offline
                                    Hansen
                                    wrote on sidst redigeret af
                                    #57

                                    Xbane lidt nyt https://xbrane.com/mfn_news/xbrane-uppdaterar-kring-fdas-granskning-av-ranibizumab-biosimilarkandidat/

                                    1 Reply Last reply
                                    0
                                    • H Offline
                                      H Offline
                                      Hansen
                                      wrote on sidst redigeret af
                                      #58

                                      Xbrane 🙂

                                      1 Reply Last reply
                                      0
                                      • F Offline
                                        F Offline
                                        Fandel
                                        wrote on sidst redigeret af
                                        #59

                                        Godmorgen...

                                        1 Reply Last reply
                                        0
                                        • L Offline
                                          L Offline
                                          LP90
                                          wrote on sidst redigeret af
                                          #60

                                          Godmorgen 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper